Alteration of factor VII activity by activated Fletcher factor (a plasma kallikrein): a potential link between the intrinsic and extrinsic blood-clotting systems.
Although surface contact is known to accelerate the one-stage prothrombin time of human plasma through the participation of Hageman factor (factor XII) and factor VII, it has not been clear whether Hageman factor interacts with factor VII directly or indirectly. Recently, Gjønnaess reported experiments suggesting that plasma kallikrein was an intermediate between Hageman factor and factor VII. The present study was undertaken to elucidate the interaction of plasma kallikrein and factor VII. Incubation of Fletcher-trait plasma (deficient in a plasma prekallikrein) with kaolin at 0 degrees C. did not induce shortening of the Thrombotest time or enhancement of factor VII activity, in contrast to studies of normal plasma. Monospecific rabbit antiserum against plasma kallikrein blocked the shortening of the Thrombotest time of normal plasma brought about by kaolin. Purified Hageman factor fragments (prekallikrein activator) induced an increase in factor VII activity in normal or Hageman-trait plasma, but not in Fletcher-trait plasma. A purified plasma kallikrein preparation enhanced factor VII activity in all plasmas, including that of Fletcher-trait plasma. The effect of the kallikrein preparation was blocked by soybean trypsin inhibitor, Trasylol, or rabbit antiserum against kallikrein, but not by lima bean trypsin inhibitor or antiserum against Hageman factor. The activity of partially purified factor VII was enhanced by purified kallikrein in the presence, but not in the absence of factor VII-deficient plasma. These results further support the idea that the enhancement of factor VII activity by surface contact is via Hageman factor and plasma kallikrein, suggesting a possible link between the intrinsic and extrinsic pathway of blood clotting. The significance of this phenomenon in hemostasis in vivo remains to be elucidated.
D000818:Animals; D007611:Aprotinin / Q000494:pharmacology; D001777:Blood Coagulation; D002850:Chromatography, Gel; D005167:Factor VII / Q000302:isolation & purification / Q000494:pharmacology*; D005168:Factor VII Deficiency / Q000097:blood; D005174:Factor XII; D006487:Hemostasis; D006801:Humans; D007106:Immune Sera; D007610:Kallikreins / Q000276:immunology / Q000302:isolation & purification / Q000494:pharmacology*; D007616:Kaolin / Q000494:pharmacology; D008970:Molecular Weight; D011517:Prothrombin Time; D011817:Rabbits / Q000276:immunology; D012995:Solubility; D013025:Glycine max; D013997:Time Factors; D014361:Trypsin Inhibitors / Q000494:pharmacology
D007106:Immune Sera; D014361:Trypsin Inhibitors; D007616:Kaolin; D005167:Factor VII; D005174:Factor XII; D007611:Aprotinin; D007610:Kallikreins